Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxercalciferol injection for secondary hyperparathyroidism in maintenance hemodialysis
ChiCTR2100052077Phase 3Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of doxercalciferol in secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD), sponsored by Renji Hospital. Primary endpoint: Intact parathyroid hormone (iPTH). Planned start Dec 2019; status: not yet recruiting.
02
Drugs
doxercalciferol
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2100052077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052077.